Valor de la trabectedina en pacientes diagnosticadas de cáncer de ovario platino-resistente para la reversión de la resistencia a platinosreintroducción del tratamiento basado en platinos tras tratamiento con Trabectedina en esta subpoblación de pacientes

Abstract

Ovarian cancer with early relapse, classically called ‘platinum-resistant’, implies a substantial shortening in the life expectancy of the patient and constitutes a huge therapeutic challenge. The probability of a response to a platinum-based chemotherapy is usually very low and current standard therapies account with poor therapeutic results in this setting. The hypothesis of this doctoral thesis focuses on questioning whether trabectedin could reverse, at least in part, the resistance to platinum. After exposure to trabectedin, platinum salts could induce a response or stabilization of the ovarian cancer and could contribute to induce a greater clinical benefit compared to the currently approved standard therapies in platinum-resistant disease (monotherapy +/- bevacizumab)...